Emblem Corp Stock (TSXV: EMC) (OTC: EMMBF) - Investor Dashboard


➔ Emblem Corp.
TSX Venture Exchange: EMC
OTC Ticker: EMMBF
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada
Employees:  68
Established: 2013
CEO: Gordon Fox

Summary

Fiscal Year-End: December
License Renewal Month: August
Licenses: 1
Licensed Capacity:  700kg
Number of Patients: N/A
Headquarters: Toronto, Ontario

Financials 9/30/16 Pro Forma

Cash on hand: $27.3mm
Fixed Investment: $9.1mm
Shareholders’ Equity: $32.0mm
Revenues – Last Quarter: $38K
Adj. Gross Margin : -1927%
EPS : N/A

Capital Structure (1/31/17)

Last Financing:  4.4mm units at $3.63
Basic Shares: 69.5mm
Warrants: 30.4mm
Options: 5.7mm
Diluted Shares: 119.7mm

Looking for data that isn’t here or have a question? Let us know.


Company Brief

Emblem Cannabis, a fully integrated Canadian healthcare and pharmaceutical company with the potential in a recreational marijuana market, to be generating $100 million in revenue, is led by a team of healthcare and Big Pharma executives, who have founded and run multi-billion dollar companies and have invested into the company.

Emblem has a clear strategy across three verticals of marijuana production, patient education, and pharmaceutical production and is uniquely positioned within Canada’s large and growing medical and recreational marijuana industry. Emblem has a high quality, experienced management team who has aligned interests with shareholders by investing $6MM and has developed a track record of building successful multi-billion dollar healthcare companies.

With a state-of-the-art production facility in Paris, Ontario up and running, Emblem’s first sales commenced in August, 2016. A planned expansion will allow a total production capacity of up to 16,000KG run rate.

Featured Video


Highlights

  • 3-pronged strategy involving cannabis production, pharmaceutical production and patient education
  • Strong management team, with executives from healthcare and pharmaceutical industries who have made substantial investment into the company
  • $32mm capital raised in 2016 enabling expansion of production capacity

Growth Strategy

  • Expansion of cannabis production capacity using capital raised in 2016
  • Unique pharmaceutical formulations including gel caps, trans-dermal patches and pills
  • Patient acquisition through GrowWise Health clinics
  • Creation of premium products for the recreational market

Differentiators

  • In-house patient education provider in 50%-owned Growwise Health
  • Pharmaceutical division headed by John Stewart, a former pharmaceutical executive who was CEO at Purdue Pharma
  • Partnership with Lift, a leading cannabis information provider, to offer Liv by Lift, a limited edition strain
  • No irradiation of product

Producing Medical Cannabis in Ontario

Gordon Fox, CEO of Emblem Corp and John Stewart, President of Emblem Pharmaceuticals, describe this company’s plans for producing medical cannabis in Ontario.


Institutional Analyst Coverage

JASON ZANDBERG
PI Financial
RESEARCH REPORT

DANIEL PEARLSTEIN
Dundee Capital Markets

RUSSELL STANLEY
Echelon Wealth Partners


Curated Stories & News


Visit Emblem Corp.,
at www.emblemcannabis.com.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Emblem Corp., is a client of NCV Media, LLC. Read our full disclaimer.

Latest News
Get The App

Download the free “New Cannabis Ventures” app on the iOS App Store or Google Play and get real-time push notifications straight to your phone on the latest breaking news and exclusives published.


ncv-news-ios-app-store

ncv-news-google-play

NCV Media, LLC

Thank you for reading

New Cannabis Ventures

Contributing original content and curating quality news on only the most promising cannabis companies and the most influential investors.

FOLLOW US ON